Trial Search Results
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
The main purpose of this research study is to learn if Inotuzumab Ozogamicin is a more effective treatment when compared to chemotherapies commonly used in patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL). Also, what the side effects are associated to inotuzumab ozogamicin treatment and how it distributes through the body will be assessed.
Stanford is currently not accepting patients for this trial.
Collaborator: UCB Pharma
- Drug: inotuzumab ozogamicin
- Drug: FLAG (fludarabine, cytarabine and G-CSF)
- Drug: HIDAC (high dose cytarabine)
- Drug: cytarabine and mitoxantrone
- CD22 expression
- Adequate liver and renal functions
- Isolated extramedullary disease
- Active Central Nervous System [CNS] disease
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study